Czechia – Antineoplastic and immunomodulating agents – Dodávky léků - REMSIMA II 2026
Opportunity Score
Confidence: 60%
Complexity: low
28 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Open tender for the supply of infliximab (REMSIMA II 2026) to the Rheumatology Institute in Prague, Czech Republic. Single lot, 36-month framework with a total estimated value of 56,164,000 CZK. Award based solely on lowest price. Submission deadline: 13 July 2026.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Supply of infliximab (ATK code L04AB02)
- Contract duration: 36 months
- Submission must be in Czech language only
Award Criteria
Cena
nejnižší celková nabídková cena včetně marže v Kč bez DPH
| Criterion | Type |
|---|---|
Cena nejnižší celková nabídková cena včetně marže v Kč bez DPH | Price |
Buyer
Name
Revmatologický ústav
Location
Praha, CZE
Buyer profile
Identifier
00023728
Lots (1)
Continuous supply of infliximab (ATC L04AB02) as per the contractual annex. One lot covering all requirements.
Procurement Details
Publication
08 Jun 2026
Deadline
13 Jul 2026, 14:30
Procedure
open
Contract
supplies
Duration
36 MONTH
Language
CES
Publication #
392956-2026
Classification
Performance: Czech Republic
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: low
28 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation